These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37069612)

  • 1. Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy.
    Tsubaki M; Takeda T; Matsuda T; Kishimoto K; Takefuji H; Taniwaki Y; Ueda M; Hoshida T; Tanabe K; Nishida S
    Cancer Cell Int; 2023 Apr; 23(1):73. PubMed ID: 37069612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
    Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
    Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-liposomal oxaliplatin combined with nuclear factor-κB inhibitor (PDTC) induces apoptosis in human colorectal cancer cells.
    Yang C; Fu ZX
    Oncol Rep; 2014 Oct; 32(4):1617-21. PubMed ID: 25174808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway.
    Wei Z; Zhou J; Yu H; Pu Y; Cheng Y; Zhang Y; Ji Q; Zhu H
    Evid Based Complement Alternat Med; 2022; 2022():3032407. PubMed ID: 36248422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intact oxaliplatin in plasma on a cold allodynia after multiple administrations in colorectal cancer model rats.
    Ito Y; Kobuchi S; Takeda M; Morimoto M
    Ann Palliat Med; 2020 Sep; 9(5):3000-3006. PubMed ID: 32692214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats.
    Nishida K; Takeuchi K; Hosoda A; Sugano S; Morisaki E; Ohishi A; Nagasawa K
    Life Sci; 2018 Aug; 207():516-524. PubMed ID: 29981320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy.
    Kobuchi S; Shimizu R; Ito AY
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32028733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases.
    Kobayashi A; Ikemura K; Wakai E; Kondo M; Okuda M
    Anticancer Res; 2023 Dec; 43(12):5613-5620. PubMed ID: 38030205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
    Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
    Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells through Its Effects on miR-409-3p.
    Han W; Yin H; Ma H; Wang Y; Kong D; Fan Z
    Evid Based Complement Alternat Med; 2020; 2020():8394574. PubMed ID: 33014113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of autophagy in the treatment of colon cancer by chlorin e6 photodynamic therapy combined with oxaliplatin.
    Luo M; Ji J; Yang K; Li H; Kang L
    Photodiagnosis Photodyn Ther; 2022 Dec; 40():103082. PubMed ID: 36028170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
    Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
    Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.
    Zhang Y; Xu Z; Sun Y; Chi P; Lu X
    Onco Targets Ther; 2018; 11():809-821. PubMed ID: 29497313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression.
    Song Y; Kang Y; Lin Z; Zeng M; Shi P; Lin J; Lu P; Luo L; Cao Y; Zhu X
    J Cancer; 2021; 12(7):1952-1959. PubMed ID: 33753993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-κB/Nrf-2 Axis.
    Campolo M; Lanza M; Paterniti I; Filippone A; Ardizzone A; Casili G; Scuderi SA; Puglisi C; Mare M; Memeo L; Cuzzocrea S; Esposito E
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
    Machover D; Diaz-Rubio E; de Gramont A; Schilf A; Gastiaburu JJ; Brienza S; Itzhaki M; Metzger G; N'Daw D; Vignoud J; Abad A; Francois E; Gamelin E; Marty M; Sastre J; Seitz JF; Ychou M
    Ann Oncol; 1996 Jan; 7(1):95-8. PubMed ID: 9081400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
    Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
    Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.